

Michelle S Hirsch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6591177/publications.pdf>

Version: 2024-02-01

165
papers

9,939
citations

41258

49
h-index

38300

95
g-index

168
all docs

168
docs citations

168
times ranked

11989
citing authors

#	ARTICLE	IF	CITATIONS
1	Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship. <i>American Journal of Surgical Pathology</i> , 2007, 31, 161-169.	2.1	980
2	High grade serous ovarian carcinomas originate in the fallopian tube. <i>Nature Communications</i> , 2017, 8, 1093.	5.8	515
3	Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy. <i>Science</i> , 2011, 334, 1129-1133.	6.0	502
4	Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models. <i>Cancer Cell</i> , 2013, 24, 751-765.	7.7	488
5	A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors. <i>American Journal of Surgical Pathology</i> , 2011, 35, 816-826.	2.1	402
6	Serous Tubal Intraepithelial Carcinoma: Its Potential Role in Primary Peritoneal Serous Carcinoma and Serous Cancer Prevention. <i>Journal of Clinical Oncology</i> , 2008, 26, 4160-4165.	0.8	317
7	PD-L1 expression in nonclear-cell renal cell carcinoma. <i>Annals of Oncology</i> , 2014, 25, 2178-2184.	0.6	249
8	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 632-648.e8.	7.7	230
9	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. <i>Journal of Clinical Oncology</i> , 2014, 32, 1889-1894.	0.8	229
10	Oncogenic mutations in cervical cancer. <i>Cancer</i> , 2013, 119, 3776-3783.	2.0	225
11	PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 627-635.	2.1	201
12	Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. <i>Modern Pathology</i> , 2015, 28, 80-94.	2.9	190
13	Perivascular Epithelioid Cell Neoplasm (PEComa) of the Gynecologic Tract. <i>American Journal of Surgical Pathology</i> , 2014, 38, 176-188.	2.1	165
14	Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer Oncogene <i>CD44</i> . <i>Science Translational Medicine</i> , 2012, 4, 147ra112.	5.8	157
15	Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers. <i>Cancer Research</i> , 2014, 74, 1141-1152.	0.4	151
16	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 461-493.	1.2	143
17	Genomic evolution and chemoresistance in germ-cell tumours. <i>Nature</i> , 2016, 540, 114-118.	13.7	139
18	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1392-1424.	2.9	138

#	ARTICLE	IF	CITATIONS
19	PAX8 Expression in Well-differentiated Pancreatic Endocrine Tumors: Correlation With Clinicopathologic Features and Comparison With Gastrointestinal and Pulmonary Carcinoid Tumors. <i>American Journal of Surgical Pathology</i> , 2010, 34, 723-729.	2.1	130
20	Atypical Genital Nevi. <i>American Journal of Surgical Pathology</i> , 2008, 32, 51-57.	2.1	127
21	GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1411-1419.	2.1	124
22	Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. <i>Cancer</i> , 2010, 116, 5219-5225.	2.0	121
23	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1167-1184.	2.9	118
24	Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 7667-7673.	3.2	113
25	Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract. <i>Modern Pathology</i> , 2015, 28, 1504-1514.	2.9	111
26	Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract. <i>American Journal of Surgical Pathology</i> , 2018, 42, 227-233.	2.1	110
27	High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. <i>Modern Pathology</i> , 2010, 23, 1316-1324.	2.9	109
28	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , 2020, 38, 63-70.	0.8	109
29	Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer. <i>PLoS ONE</i> , 2012, 7, e30269.	1.1	107
30	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 279-292.	2.1	101
31	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. <i>PLoS ONE</i> , 2013, 8, e67306.	1.1	98
32	BRAF Mutations in Metanephric Adenoma of the Kidney. <i>European Urology</i> , 2012, 62, 917-922.	0.9	95
33	Collecting Duct Carcinoma Versus Renal Medullary Carcinoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 871-874.	2.1	90
34	Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. <i>Human Pathology</i> , 2017, 63, 149-156.	1.1	89
35	Coexisting Intraepithelial Serous Carcinomas of the Endometrium and Fallopian Tube: Frequency and Potential Significance. <i>International Journal of Gynecological Pathology</i> , 2009, 28, 308-315.	0.9	86
36	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	5.8	84

#	ARTICLE	IF	CITATIONS
37	Serous Tubal Intraepithelial Carcinoma: Diagnostic Reproducibility and its Implications. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 310-314.	0.9	83
38	Clear Cell-Papillary Renal Cell Carcinoma of the Kidney Not Associated With End-stage Renal Disease. <i>American Journal of Surgical Pathology</i> , 2015, 39, 873-888.	2.1	83
39	Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. <i>Gynecologic Oncology</i> , 2011, 123, 5-12.	0.6	82
40	FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. <i>Cancer Medicine</i> , 2014, 3, 835-844.	1.3	76
41	PRKCI promotes immune suppression in ovarian cancer. <i>Genes and Development</i> , 2017, 31, 1109-1121.	2.7	75
42	Evidence Supporting the Existence of Benign Teratomas of the Postpubertal Testis. <i>American Journal of Surgical Pathology</i> , 2013, 37, 827-835.	2.1	70
43	Radical Retropubic Prostatectomy and Robotic-assisted Laparoscopic Prostatectomy: Likelihood of Positive Surgical Margin(s). <i>Urology</i> , 2010, 76, 1097-1101.	0.5	65
44	Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. <i>Nature Medicine</i> , 2016, 22, 685-691.	15.2	64
45	Validation of a TFE3 Break-apart FISH Assay for Xp11.2 Translocation Renal Cell Carcinomas. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 129-137.	2.1	60
46	Thyroid transcription factor-1, but not p53, is helpful in distinguishing moderately differentiated neuroendocrine carcinoma of the larynx from medullary carcinoma of the thyroid. <i>Modern Pathology</i> , 2004, 17, 631-636.	2.9	57
47	Overexpression of Elafin in Ovarian Carcinoma Is Driven by Genomic Gains and Activation of the Nuclear Factor κ B Pathway and Is Associated with Poor Overall Survival. <i>Neoplasia</i> , 2010, 12, 161-IN15.	2.3	56
48	Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. <i>Science Translational Medicine</i> , 2016, 8, 329ra34.	5.8	54
49	Embryonic Stem Cell Transcription Factors and D2-40 (Podoplanin) as Diagnostic Immunohistochemical Markers in Ovarian Germ Cell Tumors. <i>International Journal of Gynecological Pathology</i> , 2009, 28, 347-355.	0.9	53
50	Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. <i>Lancet Oncology</i> , The, 2013, 14, 81-87.	5.1	52
51	The Role of CD10 Staining in Distinguishing Invasive Endometrial Adenocarcinoma from Adenocarcinoma Involving Adenomyosis. <i>Modern Pathology</i> , 2003, 16, 22-27.	2.9	48
52	Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. <i>Modern Pathology</i> , 2008, 21, 937-942.	2.9	47
53	Stathmin 1 and p16INK4A are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. <i>Gynecologic Oncology</i> , 2015, 139, 104-111.	0.6	47
54	High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary. <i>PLoS ONE</i> , 2011, 6, e24433.	1.1	44

#	ARTICLE	IF	CITATIONS
55	Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. <i>International Journal of Cancer</i> , 2008, 123, 569-576.	2.3	43
56	Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. <i>Modern Pathology</i> , 2009, 22, 985-988.	2.9	43
57	Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1389-1401.	3.2	43
58	In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1102-1107.	3.3	42
59	β-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers. <i>Gynecologic Oncology</i> , 2014, 134, 426-427.	0.6	42
60	Evaluation of vascular space involvement in endometrial adenocarcinomas: laparoscopic vs abdominal hysterectomies. <i>Modern Pathology</i> , 2010, 23, 1073-1079.	2.9	41
61	Integrative clinical and molecular characterization of translocation renal cell carcinoma. <i>Cell Reports</i> , 2022, 38, 110190.	2.9	40
62	<scp>GATA</scp>3 expression in gestational trophoblastic tissues and tumours. <i>Histopathology</i> , 2015, 67, 636-644.	1.6	39
63	Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma. <i>Human Pathology</i> , 2017, 67, 134-145.	1.1	38
64	Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer. <i>Cancer Research</i> , 2019, 79, 760-772.	0.4	38
65	Histological "progression"™ from low (LSIL) to high (HSIL) squamous intraepithelial lesion is an uncommon event and an indication for quality assurance review. <i>Modern Pathology</i> , 2010, 23, 1045-1051.	2.9	36
66	Loss of SMAD4 protein expression in gastrointestinal and extra-gastrointestinal carcinomas. <i>Histopathology</i> , 2019, 75, 546-551.	1.6	35
67	Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2009, 115, 401-406.	0.6	34
68	Adult Renal Cell Carcinoma. <i>Surgical Pathology Clinics</i> , 2015, 8, 587-621.	0.7	33
69	Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). <i>International Journal of Gynecological Pathology</i> , 2019, 38, 230-240.	0.9	33
70	The Role of Pathology Correlation Approach in Prostate Cancer Index Lesion Detection and Quantitative Analysis with Multiparametric MRI. <i>Academic Radiology</i> , 2015, 22, 548-555.	1.3	32
71	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. <i>American Journal of Surgical Pathology</i> , 2020, 44, 673-680.	2.1	31
72	Stathmin-1 Expression as a Complement to p16 Helps Identify High-grade Cervical Intraepithelial Neoplasia With Increased Specificity. <i>American Journal of Surgical Pathology</i> , 2013, 37, 89-97.	2.1	29

#	ARTICLE	IF	CITATIONS
73	FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. <i>Oncogene</i> , 2014, 33, 4424-4432.	2.6	29
74	Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 928-938.	3.2	29
75	Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes. <i>Histopathology</i> , 2020, 77, 659-666.	1.6	28
76	Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology. <i>Abdominal Radiology</i> , 2017, 42, 918-925.	1.0	26
77	A Case of Adult Metastatic Xp11 Translocation Renal Cell Carcinoma Treated Successfully With Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2009, 7, E93-E94.	0.9	25
78	HNF1 β and S100A1 are useful biomarkers for distinguishing renal oncocytoma and chromophobe renal cell carcinoma in FNA and core needle biopsies. <i>Cancer Cytopathology</i> , 2015, 123, 298-305.	1.4	25
79	Prostatic Metaplasia of the Vagina and Uterine Cervix. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1040-1049.	2.1	25
80	Smoothelin Is a Specific Marker for Smooth Muscle Neoplasms of the Gastrointestinal Tract. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1795-1801.	2.1	24
81	Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma. <i>Histopathology</i> , 2015, 66, 901-904.	1.6	23
82	Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation. <i>Magnetic Resonance Imaging</i> , 2015, 33, 886-894.	1.0	23
83	Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. <i>Journal of Pathology</i> , 2018, 246, 459-469.	2.1	23
84	Challenges in Pathologic Staging of Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1253-1261.	2.1	22
85	PAX8 and PAX5 are differentially expressed in B-cell and T-cell lymphomas. <i>Histopathology</i> , 2013, 62, 406-413.	1.6	21
86	“Embryonic-type Neuroectodermal Tumor” Should Replace “Primitive Neuroectodermal Tumor” of the Testis and Gynecologic Tract. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1299-1302.	2.1	21
87	Mucinous tubular and spindle cell carcinoma of the kidney: imaging features. <i>Cancer Imaging</i> , 2012, 12, 66-71.	1.2	20
88	SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance. <i>Oncogenesis</i> , 2016, 5, e264-e264.	2.1	20
89	<sc>PNL</sc>2: an adjunctive biomarker for renal angiomyolipomas and perivascular epithelioid cell tumours. <i>Histopathology</i> , 2018, 72, 441-448.	1.6	20
90	A Comprehensive Review of Biomarker Use in the Gynecologic Tract Including Differential Diagnoses and Diagnostic Pitfalls. <i>Advances in Anatomic Pathology</i> , 2020, 27, 164-192.	2.4	20

#	ARTICLE	IF	CITATIONS
91	Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. <i>Modern Pathology</i> , 2022, 35, 836-849.	2.9	20
92	Multiple asymptomatic plexiform schwannomas of the sigmoid colon: A case report and review. <i>Gastrointestinal Endoscopy</i> , 2001, 53, 801-804.	0.5	19
93	Pagetoid Lesions of the Vulva. <i>International Journal of Gynecological Pathology</i> , 2008, PAP, 292-6.	0.9	19
94	Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. <i>Gynecologic Oncology</i> , 2014, 132, 328-333.	0.6	17
95	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. <i>Cancer</i> , 2016, 122, 2389-2398.	2.0	16
96	PNL2: A Useful Adjunct Biomarker to HMB45 in the Diagnosis of Uterine Perivascular Epithelioid Cell Tumor (PEComa). <i>International Journal of Gynecological Pathology</i> , 2020, 39, 529-536.	0.9	16
97	Comparative molecular analysis of testicular Leydig cell tumors demonstrates distinct subsets of neoplasms with aggressive histopathologic features. <i>Modern Pathology</i> , 2021, 34, 1935-1946.	2.9	15
98	Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey. <i>Journal of Clinical Pathology</i> , 2021, 74, 291-299.	1.0	14
99	Non-clear cell renal cell carcinoma, part 2: therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 383-91.	0.3	14
100	Teratoma with malignant transformation: report of three cases and review of the literature. <i>Clinical Imaging</i> , 2014, 38, 589-593.	0.8	13
101	Pseudosarcomatous myofibroblastic proliferations of the urinary bladder are neoplasms characterized by recurrent FN1-ALK fusions. <i>Modern Pathology</i> , 2021, 34, 469-477.	2.9	12
102	Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. <i>European Urology</i> , 2022, 81, 466-473.	0.9	12
103	A Weakly Positive Human Papillomavirus Hybrid Capture II Result Correlates With a Significantly Lower Risk of Cervical Intraepithelial Neoplasia 2,3 After Atypical Squamous Cells of Undetermined Significance Cytology. <i>Journal of Lower Genital Tract Disease</i> , 2010, 14, 174-178.	0.9	11
104	Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT101070001). <i>Journal of Clinical Oncology</i> , 2015, 33, 1010-1017.	0.5	11
105	Interobserver reproducibility of the diagnosis of differentiated exophytic vulvar intraepithelial lesion (DEVIL) and the distinction from its mimics. <i>Histopathology</i> , 2021, 79, 957-965.	1.6	11
106	The Differential Diagnosis of Medullary-Based Renal Masses. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1148-1170.	1.2	11
107	Intestinal metaplasia of the urinary tract harbors potentially oncogenic genetic variants. <i>Modern Pathology</i> , 2021, 34, 457-468.	2.9	9
108	Molecular assessment of testicular adult granulosa cell tumor demonstrates significant differences when compared to ovarian counterparts. <i>Modern Pathology</i> , 2022, 35, 697-704.	2.9	9

#	ARTICLE	IF	CITATIONS
109	Molecular and immunohistochemical characterisation of mesothelioma of the tunica vaginalis. Histopathology, 2022, 81, 65-76.	1.6	9
110	Early-stage clear cell tubulopapillary renal cell carcinoma: imaging features and distinction from clear cell and papillary subtypes. Abdominal Radiology, 2016, 41, 2187-2195.	1.0	7
111	De Novo Tumors of Teratoma. International Journal of Gynecological Pathology, 2018, 37, 296-300.	0.9	7
112	Squamous Cell Carcinoma of the Bladder Is Not Associated With High-risk HPV. Urology, 2020, 144, 158-163.	0.5	7
113	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 295.e1-295.e8.	0.8	6
114	Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference. European Journal of Cancer, 2022, 173, 59-70.	1.3	6
115	The Effect of Differing Gleason Scores at Biopsy on the Odds of Upgrading and the Risk of Death From Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, e181-e187.	0.9	5
116	Detecting metastatic prostate carcinoma in pelvic lymph nodes following neoadjuvant hormone therapy: the eyes have it!. Histopathology, 2016, 68, 303-307.	1.6	5
117	Primary mucinous adenocarcinoma of the seminal vesicle associated with intestinal metaplasia: a radiation-induced tumour?. Histopathology, 2021, 79, 444-448.	1.6	5
118	Expression of the C-terminal region of the SSX protein is a useful diagnostic biomarker for spermatocytic tumour. Histopathology, 2021, 79, 700-707.	1.6	5
119	SOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia. American Journal of Surgical Pathology, 2022, 46, 213-219.	2.1	5
120	PD-L1 expression in non-clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 424-424.	0.8	5
121	p53 null phenotype is a positive result in urothelial carcinoma in situ. Modern Pathology, 2022, 35, 1287-1292.	2.9	5
122	PAX8 Distinguishes Diffuse Large B-Cell Lymphoma Mimicking Sarcoma. Case Reports in Pathology, 2017, 2017, 1-5.	0.2	4
123	Volume of Gleason pattern 4 stratifies risk of metastasis and death in patients with Gleason score 3+5=8/5+3=8 positive prostate core biopsies. Human Pathology, 2020, 99, 62-74.	1.1	4
124	Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. American Journal of Cancer Research, 2021, 11, 3990-4001.	1.4	4
125	A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression. International Journal of Surgical Pathology, 2022, 30, 606-615.	0.4	4
126	Maximum Tumor Diameter and the Risk of Prostate-Specific Antigen Recurrence After Radical Prostatectomy. Clinical Genitourinary Cancer, 2014, 12, e173-e179.	0.9	3

#	ARTICLE	IF	CITATIONS
127	MRI-targeted prostate biopsy: key considerations for pathologists. <i>Histopathology</i> , 2020, 77, 18-25.	1.6	3
128	A Comparison of Genitourinary Pathology Society (GUPS) and International Society of Urological Pathology (ISUP) Prostate Cancer Grading Guidelines. <i>American Journal of Surgical Pathology</i> , 2021, Publish Ahead of Print, 1005-1007.	2.1	3
129	Clinical characterization of radiation-associated muscle-invasive bladder cancer. <i>Urology</i> , 2021, 154, 208-214.	0.5	3
130	Cyclophosphamide-associated bladder cancers and considerations for survivorship care: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 678-685.	0.8	3
131	KRAS and EGFR mutations to distinguish adenocarcinomas and squamous cell carcinomas of the cervix. <i>Journal of Clinical Oncology</i> , 2012, 30, 5011-5011.	0.8	3
132	Clear cell tubopapillary renal cell carcinoma mimicking polycystic kidney disease: A case report. <i>Urology Case Reports</i> , 2018, 16, 35-37.	0.1	2
133	p-120 Catenin is a Useful Diagnostic Biomarker for Distinguishing Plasmacytoid and Sarcomatoid Variants From Conventional Urothelial Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1000-1008.	1.2	2
134	Preface. <i>Surgical Pathology Clinics</i> , 2015, 8, xi.	0.7	1
135	Metastatic Tumors Involving the Ovary. , 2018, , 1050-1069.		1
136	An Unusual Cause of Secondary Amenorrhea in an Adolescent: Expanding the Differential. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa159.	0.1	1
137	Clinicopathological and molecular characteristics of prostate cancer diagnosed in young men aged up to 45 years. <i>Histopathology</i> , 2021, 78, 857-870.	1.6	1
138	Key Renal Neoplasms With a Female Predominance. <i>Advances in Anatomic Pathology</i> , 2021, 28, 228-250.	2.4	1
139	Grading Intraductal Carcinoma in Prostate Biopsies Changes Risk Categorization in a Small Subset of Cases. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 782-784.	1.2	1
140	Low-Grade Fumarate Hydratase-Deficient Renal Cell Carcinoma in a 30-Year-Old Female. <i>International Journal of Surgical Pathology</i> , 2022, 30, 184-189.	0.4	1
141	Detecting lower in addition to the highest Gleason score prostate cancer on core biopsy and the odds of upgrading at radical prostatectomy. <i>Journal of Clinical Oncology</i> , 2013, 31, e16026-e16026.	0.8	1
142	Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT). <i>Journal of Clinical Oncology</i> , 2016, 34, 485-485.	0.8	1
143	Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 332-332.	0.8	1
144	PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target?. <i>Journal of Clinical Oncology</i> , 2012, 30, 4582-4582.	0.8	1

#	ARTICLE	IF	CITATIONS
145	Multidisciplinary care and management of very low-risk prostate cancer.. Journal of Clinical Oncology, 2013, 31, 55-55.	0.8	1
146	PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.. Journal of Clinical Oncology, 2014, 32, 4526-4526.	0.8	1
147	Granulomas associated with renal neoplasms: A multi-institutional clinicopathological study of 111 cases. Histopathology, 2022, , .	1.6	1
148	Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index. Blood, 2011, 118, 1442-1442.	0.6	0
149	Genetic polymorphismsâ€™ influence in outcome of metastatic renal cell cancer patients treated with VEGF-targeted agents.. Journal of Clinical Oncology, 2012, 30, 4635-4635.	0.8	0
150	Association of inherited genetic variation with clinical outcome in patients with advanced renal cell carcinoma treated with mTOR inhibition.. Journal of Clinical Oncology, 2012, 30, 4543-4543.	0.8	0
151	A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates.. Journal of Clinical Oncology, 2013, 31, 278-278.	0.8	0
152	A 10-year retrospective review of germ cell tumors not cured with cisplatin-based chemotherapy.. Journal of Clinical Oncology, 2013, 31, 325-325.	0.8	0
153	Smoking history and disease outcomes in patients with malignant germ cell tumors.. Journal of Clinical Oncology, 2013, 31, 4561-4561.	0.8	0
154	Clinicopathologic features and clinical outcomes associated with Gleason upgrading from biopsy to radical prostatectomy.. Journal of Clinical Oncology, 2013, 31, 5056-5056.	0.8	0
155	Tumor genomic mutation profiling of germ cell tumors using â€œProfileâ€. Journal of Clinical Oncology, 2014, 32, 4516-4516.	0.8	0
156	Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC).. Journal of Clinical Oncology, 2015, 33, 365-365.	0.8	0
157	Emerging and Recently Described Subtypes of Renal Carcinoma. , 2016, , 125-140.		0
158	Abstract A18: Development of a novel peptide therapeutic that targets ovarian cancer via the tumor microenvironment. , 2016, , .		0
159	Abstract 1425: Targeting cell cycle dependencies in CCNE1 amplified tumors. , 2017, , .		0
160	Kidney: Papillary adenoma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018, , .	0.1	0
161	Kidney: Metanephric adenoma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018, , .	0.1	0
162	Kidney: Renal Oncocytoma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018, , .	0.1	0

#	ARTICLE	IF	CITATIONS
163	Genomic profiling of variant urinary tract tumor histologies.. Journal of Clinical Oncology, 2019, 37, 450-450.	0.8	0
164	Abstract B27: Cellular retinoic acid binding protein 2 (CRABP2) is a novel biomarker and potential therapeutic target for high-grade serous ovarian carcinomas. , 2020, , .		0
165	â€œCase of the Monthâ€™ from Brigham and Womenâ€™s Hospital, Boston, MA, USA: a 70â€™yearâ€™old man with lung cysts and bilateral renal masses. BJU International, 2020, 126, 428-432.	1.3	0